Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment
PR99379
ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire=KYODO JBN/ --
Study met all primary endpoints
Alphyn Biologics (
), a clinical-stage dermatology company developing first-in-class multi-target
therapeutics, announced today positive results from the first cohort of its
Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate
atopic dermatitis (AD). The trial met all of its primary endpoints,
highlighting AB-101a's potential to be an effective and safe treatment for AD.
Logo -
The randomized, vehicle-controlled, double-blind trial is evaluating the
treatment protocol of AB-101a across multiple sites using standard scales for
assessing AD. The trial, conducted in Australia, enrolled 41 AD patients, and
treatment was evaluated after four weeks.
"As a physician who treated 15 percent of the patients in the clinical trial, I
am encouraged by the results with AB-101a," said Dr. Stephen Shumack, Clinical
Associate Professor Dermatology, University of Sydney, and Principal
Investigator at St George Dermatology & Skin Cancer Centre. "I look forward to
future trials and gaining a better understanding of AB-101a's potential
benefits for patients."
"Patients with mild-to-moderate atopic dermatitis suffer considerably from the
symptoms of this often debilitating disease, yet available treatments come with
side effects and safety concerns," said Alphyn CEO Neal Koller. "We are excited
by these results and look forward to the results of our ongoing cohort treating
infected AD. We plan to further study AB-101a in a Phase 2b/3 trial this year
in conjunction with a Series B financing."
Alphyn intends to present the full results of this trial at a scientific
conference and submit a paper for publication in a peer-reviewed journal.
Enrollment is ongoing in the second cohort of the Phase 2a clinical trial. This
cohort is investigating the unique ability of AB-101a to treat the infected
component of AD in AD patients who are suffering from bacterial infections,
including Staphylococcus aureus, or "Staph," and MRSA, the antibiotic-resistant
Staph. Alphyn anticipates AB-101a will be effective in treating non-infected AD
and infected AD. AB-101a should provide AD patients and physicians a
comprehensive, safe, and convenient treatment option.
AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform
has multiple bioactive compounds and, therefore, multiple mechanisms of action
to address multiple problems of any target disease. Alphyn was able to begin
the AB-101a clinical trial program in Phase 2 due to the strong safety profile
of its AB-101 platform.
ABOUT ALPHYN BIOLOGICS
Alphyn Biologics is a clinical-stage dermatology company developing
first-in-class multi-target therapeutics for severe and prevalent skin diseases
based on its AB-101 platform. Its lead product candidate, AB-101a, is being
developed as a topical treatment for atopic dermatitis (AD), the most common
form of eczema. AB-101a has demonstrated a strong safety profile and is in
development to uniquely target AD's immune system and bacterial components,
making it ideal for treating AD and infected AD. Alphyn's AB-101 platform has
multiple bioactive compounds and therefore multiple mechanisms of action to
support a robust pipeline of dermatologic therapeutics that have potential
safety, efficacy and regulatory marketing authorization advantages. Alphyn is
based in Annapolis, Maryland and Cincinnati, Ohio, and has a wholly owned
Australia subsidiary. The company became operational in 2020 and has raised
approximately $6.9 million.
SOURCE Alphyn Biologics
CONTACT: Corporate: Neal Koller, nkoller@alphynbiologics.com, (410) 690-8687;
Media: Susan Thomas, susan@endpointcommunications.net, (619) 540-9195
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
